Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Frontline T-DM1 on Horizon in Metastatic Breast Cancer

November 20th 2014

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

Fewer CNS Metastases, Similar Efficacy Seen With Neratinib Versus Trastuzumab

November 14th 2014

Frontline treatment with neratinib in combination with paclitaxel demonstrated similar ORR and PFS as the combination of trastuzumab and paclitaxel while lowering the incidence of CNS metastases in patients with locally recurrent or metastatic HER2-positive breast cancer.

Novel Radiotherapy Techniques Expand Options for Breast Cancer Patients

November 12th 2014

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

Development of PI3K Inhibitors in Breast Cancer

November 7th 2014

The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.

Expert Critiques Adjuvant Tamoxifen Guideline for HR-Positive Breast Cancer

November 6th 2014

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

Eribulin Improves Survival in Metastatic Triple-Negative Breast Cancer

November 3rd 2014

Treatment with eribulin mesylate improved overall survival of patients with triple-negative and HER2-negative metastatic breast cancer compared with standard chemotherapies.

Dr. Mamounas on Selecting Patients With Breast Cancer for Neoadjuvant Chemotherapy

October 23rd 2014

Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

Expert Says pCR Data Support Neoadjuvant Therapy in HER2-Positive Breast Cancer

October 22nd 2014

Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care

Dr. Yao Discusses Sources of Information on Decisions Regarding Contralateral Prophylactic Mastectomy

October 20th 2014

Katharine Yao, MD, director, breast surgical program, NorthShore University HealthSystem, Evanston, Illinois, clinical associate professor, surgery, Pritzker School of Medicine, University of Chicago, discusses a prospective study that analyzed the sources of information regarding decisions on contralateral prophylactic mastectomy.

Dr. Swain on the Impact of Chemotherapy on Outcomes in HER2-Positive Metastatic Breast Cancer

October 15th 2014

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses a taxane's impact on outcomes in patients with HER2-positive metastatic breast cancer.

FDA Expands Approval of Lymphoseek to Breast Cancer and Melanoma

October 15th 2014

The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include lymphatic mapping in solid tumors and sentinel lymph node (SLN) detection for breast cancer and melanoma

Dr. Hudis Discusses Obesity and Breast Cancer

October 15th 2014

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses obesity and its relation to breast cancer.

Priority Review Granted to Palbociclib in Breast Cancer

October 13th 2014

The FDA has assigned a priority review designation to palbociclib in combination with letrozole as a frontline treatment for postmenopausal patients with ER-positive, HER2-negative advanced breast cancer.

New Tactics Needed for Adjuvant Therapy to Advance in Early HER2-Positive Breast Cancer

October 8th 2014

Recent research has shown that adding targeted agents to trastuzumab-based chemotherapy regimens in the adjuvant setting may not significantly improve outcomes in patients with early-stage HER2-positive breast cancer.

Pertuzumab Data Highlight Potential of Triplet Regimens in MBC

October 8th 2014

New therapeutic strategies utilizing triplet regimens for the treatment of patients with HER2-positive metastatic breast cancer (MBC) continue to emerge as an exciting area of development

Dr. Rugo Discusses How Stomatitis Impacts the Efficacy of Everolimus

October 7th 2014

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses a meta-analysis that examined how stomatitis impacts the efficacy of everolimus

Swain Provides Insight Into Updated CLEOPATRA Survival Findings

October 5th 2014

Pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median overall survival (OS) by 15.7 months over standard first-line therapy

Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast Cancer

October 3rd 2014

Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.

Taking a Value-Based Approach to Breast Cancer Screening, Workup, and Surveillance

October 2nd 2014

It is well known that healthcare spending in the United States is unsustainable. It is also well known that despite spending a record $2.8 trillion on healthcare annually (17.2% of GDP in 2012)-more than any other nation-our health outcomes lag behind.

Tumor Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer

October 2nd 2014

A high level of tumor infiltrating lymphocytes (TILs) may be a marker of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer, especially in patients with triple-negative or HER2-positive disease